RS63255B1 - 1h-indazol-3-karboksamid jedinjenja kao inhibitori glikogen sintaza kinaze 3 beta - Google Patents

1h-indazol-3-karboksamid jedinjenja kao inhibitori glikogen sintaza kinaze 3 beta

Info

Publication number
RS63255B1
RS63255B1 RS20220482A RSP20220482A RS63255B1 RS 63255 B1 RS63255 B1 RS 63255B1 RS 20220482 A RS20220482 A RS 20220482A RS P20220482 A RSP20220482 A RS P20220482A RS 63255 B1 RS63255 B1 RS 63255B1
Authority
RS
Serbia
Prior art keywords
group
indazole
mmol
alkyl
carboxamide
Prior art date
Application number
RS20220482A
Other languages
English (en)
Serbian (sr)
Inventor
Guido Furlotti
Claudia Cavarischia
Rosa Buonfiglio
Rosella Ombrato
Tommaso Iacoangeli
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of RS63255B1 publication Critical patent/RS63255B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20220482A 2018-05-07 2019-05-06 1h-indazol-3-karboksamid jedinjenja kao inhibitori glikogen sintaza kinaze 3 beta RS63255B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18171084 2018-05-07
EP19721295.4A EP3790873B1 (en) 2018-05-07 2019-05-06 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
PCT/EP2019/061532 WO2019215075A1 (en) 2018-05-07 2019-05-06 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

Publications (1)

Publication Number Publication Date
RS63255B1 true RS63255B1 (sr) 2022-06-30

Family

ID=62134122

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220482A RS63255B1 (sr) 2018-05-07 2019-05-06 1h-indazol-3-karboksamid jedinjenja kao inhibitori glikogen sintaza kinaze 3 beta

Country Status (28)

Country Link
US (1) US11472795B2 (https=)
EP (1) EP3790873B1 (https=)
JP (1) JP7411574B2 (https=)
KR (1) KR102778690B1 (https=)
CN (1) CN112135821B (https=)
AU (1) AU2019265606B2 (https=)
BR (1) BR112020021922A2 (https=)
CA (1) CA3094896A1 (https=)
CY (1) CY1125293T1 (https=)
DK (1) DK3790873T3 (https=)
EA (1) EA202092422A1 (https=)
ES (1) ES2913975T3 (https=)
GE (2) GEP20227437B (https=)
HR (1) HRP20220664T1 (https=)
HU (1) HUE058894T2 (https=)
IL (1) IL278330B2 (https=)
LT (1) LT3790873T (https=)
MA (1) MA52557A (https=)
MD (1) MD3790873T2 (https=)
MX (1) MX2020011882A (https=)
PL (1) PL3790873T3 (https=)
PT (1) PT3790873T (https=)
RS (1) RS63255B1 (https=)
SG (1) SG11202009230WA (https=)
SI (1) SI3790873T1 (https=)
SM (1) SMT202200227T1 (https=)
UA (1) UA128089C2 (https=)
WO (1) WO2019215075A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023506257A (ja) * 2019-12-16 2023-02-15 コリア リサーチ インスティチュート オブ ケミカル テクノロジー 新規なインダゾール誘導体及びその用途
CN114230565B (zh) * 2020-09-09 2023-10-27 成都奥睿药业有限公司 5-取代吲哚3-酰胺衍生物及其制备方法和用途
WO2022125377A1 (en) * 2020-12-08 2022-06-16 Disarm Therapeutics, Inc. Benzopyrazole inhibitors of sarm1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ257545A (en) 1992-11-05 1997-01-29 Smithkline Beecham Plc Heterocyclic (especially piperidine) derivatives and pharmaceutical compositions
GB0218625D0 (en) 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
ITMI20030287A1 (it) 2003-02-18 2004-08-19 Acraf Indazolammidi dotate di attivita' analgesica metodo, per
ITMI20030972A1 (it) 2003-05-15 2004-11-16 Acraf Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende.
KR101061599B1 (ko) * 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3473099A1 (en) * 2011-09-14 2019-04-24 Samumed, LLC Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
CA2860250C (en) * 2012-02-21 2020-11-10 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
RS54539B1 (sr) 2012-02-21 2016-06-30 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A. Upotreba 1h-indazol-3-karboksamidnih jedinjenja kao inhibitora kinaze 3-beta glikogen sintetaze
MX2016012208A (es) * 2014-03-20 2017-01-26 Samumed Llc Indazol-3-carboxamidas 5-substituidas y preparacion y uso de las mismas.
AU2019224075A1 (en) * 2018-02-23 2020-09-10 Samumed, Llc 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof

Also Published As

Publication number Publication date
MA52557A (fr) 2021-03-17
WO2019215075A1 (en) 2019-11-14
UA128089C2 (uk) 2024-04-03
IL278330A (https=) 2020-12-31
EP3790873A1 (en) 2021-03-17
JP7411574B2 (ja) 2024-01-11
JP2021523134A (ja) 2021-09-02
EP3790873B1 (en) 2022-04-27
CN112135821A (zh) 2020-12-25
IL278330B2 (en) 2024-06-01
KR102778690B1 (ko) 2025-03-12
US20210053956A1 (en) 2021-02-25
DK3790873T3 (da) 2022-05-23
SG11202009230WA (en) 2020-11-27
MX2020011882A (es) 2021-01-20
HRP20220664T1 (hr) 2022-06-24
MD3790873T2 (ro) 2022-07-31
SMT202200227T1 (it) 2022-07-21
EA202092422A1 (ru) 2021-02-12
BR112020021922A2 (pt) 2021-01-26
GEAP202215506A (en) 2022-07-11
IL278330B1 (en) 2024-02-01
KR20210005863A (ko) 2021-01-15
AU2019265606A1 (en) 2020-10-15
ES2913975T3 (es) 2022-06-07
AU2019265606B2 (en) 2023-10-12
CA3094896A1 (en) 2019-11-14
SI3790873T1 (sl) 2022-07-29
CN112135821B (zh) 2024-05-31
CY1125293T1 (el) 2025-03-28
LT3790873T (lt) 2022-06-10
US11472795B2 (en) 2022-10-18
HUE058894T2 (hu) 2022-09-28
PT3790873T (pt) 2022-05-11
PL3790873T3 (pl) 2022-06-27
GEP20227437B (en) 2022-11-10

Similar Documents

Publication Publication Date Title
RU2726115C1 (ru) Пиридопиримидиновые ингибиторы cdk2/4/6
CA3232128A1 (en) Pyridine derivative and use thereof
AU2013224302B2 (en) 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
WO2017023894A1 (en) Mthfd2 inhibitors and uses thereof
WO2019079626A1 (en) 6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE
CA3029097A1 (en) N-(substituted-phenyl)-sulfonamide derivatives as perk kinase inhibitors
HK1221952A1 (zh) 作为bet蛋白和极体样激酶的双重抑制剂的取代的二氢吡啶并[3,4-b]吡嗪酮
TW200536849A (en) Substituted heterocycles and the uses thereof
MX2008000574A (es) Nuevos derivados de 2,4-dianilinopirimidinas, la preparacion de los mismos, su uso como medicamentos, composiciones farmaceuticas y, en particular, como inhibidores ikk.
AU2013224313B2 (en) Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
CA3234750A1 (en) Modulators of sestrin-gator2 interaction and uses thereof
JP5995975B2 (ja) Mtor阻害剤としてのモルホリノ置換尿素またはカルバメート誘導体
JP5508257B2 (ja) アリールアミドピリミドン化合物
EP3790873B1 (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
JP2024537110A (ja) Ent1阻害活性を有する大環状化合物
KR20180039117A (ko) 아릴-치환된 디히드로퀴놀리논, 그의 제조법 및 제약으로서의 그의 용도
AU2019344240B2 (en) Novel thiazole derivatives and pharmaceutically acceptable salts thereof
HK40038633B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
HK40038633A (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
EA043429B1 (ru) 1h-индазол-3-карбоксамидные соединения в качестве ингибиторов киназы гликогенсинтазы 3-бета
CN120518582A (zh) 一类并环结构取代的新型cdk12/13共价抑制剂或其药物组合物和应用